Skip to main navigation Skip to search Skip to main content

A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Selonsertib in subjects with compensated cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • Hodge, Alex (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Ref number: HREC/17/SVHM/11
NMA SSA Ref number: SsA/167/MonH246
Monash Health Ref: RES-17-0000-308X
SEO Code - 920106 Endocrine Organs and Diseases (excl. Diabetes)
StatusFinished
Effective start/end date5/07/17 → 4/07/22

Clinical Trial Phase

  • Phase III (a & b)